Your company shouldn't be upgrading to trendy technology without a strategic purpose, writes this local expert. Photo via Getty Images

In any industry, the use of innovative technologies is often linked to an innovative company. With immersive technologies — including augmented reality, virtual reality, and interactive — heading into the mainstream thanks to COVID-19, brands are now able to reach their audiences in ways like never before. However, instead of incorporating these new technologies into their overall strategy, brands often fall into the trap of using the technology as their only strategy.

When brands are presented with a new and exciting way to interact with consumers in a world where it is hard to maintain their audiences' attention, it's easy to see why this happens. While these brands might get audiences' attention at the beginning when the technology is still novel, the campaign itself most likely won't make a lasting impression, especially as these technologies come more into the mainstream. Additionally, the new and shiny tactic may not be what best serves a brand's ultimate goal.

Starting with strategy

While the use of immersive technologies is growing, it is important to determine whether it is the right solution for the company.

To start, businesses should evaluate their target demographics and goals before investing in new technologies such as virtual reality, augmented reality or animation. When taking all possible stakeholders into account, it will then be easier to shape the experience for maximum engagement and connection with target audiences. For example, in our work at VISION, we once worked with a client whose CEO had told their marketing team that they wanted Google Glass AR for a tradeshow.

The marketing team said they wanted to create an immersive experience and invite existing customers and potential new customers to a private experience using this innovative new technology. However, they did not have a plan for what the experience would be or why the customers were experiencing it. They just wanted to use word of mouth to talk about how cool it was.

Our team came in and listened to the event goals, gave our recommendations, and the client then realized they needed to determine who the customer was and what they wanted to say to the customer from a sales perspective.

That same client came back with a strategy behind the tradeshow experience and ultimately realized they actually did not want an AR experience, but that they wanted a complete immersive experience. From there, this client instead chose a 3D Interactive experience that they could deliver virtually online directly to their clients, and they didn't even use it for the tradeshow. It turned out to be the most successful sales tool they had ever produced.

What tech can do for strategy

Once brands have a broader idea for their strategy and marketing goals, they also need to understand what new immersive technologies are used to accomplish. Beyond creating "buzz," how does each technology actually drive the customer experience and end action desired?

Interactive media—Interactive media is a method of communication in which a program's outputs depend on the user's inputs, and the user's inputs, in turn, affect the program's outputs. Interactive media allows brands to connect with their audiences and making them active participants in the media they consume. Examples include digital graphics, interactive video or in-person touch screen activations.

There are a lot of different forms of interactive media, but at the heart, the goal of this tactic is to create something personalized to the user and establish a memorable connection.

Consider that people remember very little of what they read. They are likely to remember more if they view it in a video format – but they are most likely to remember something they have had a role in themselves. This makes it a particularly compelling technology if the ultimate goal is around education or awareness of a new topic.

Augmented reality – Augmented reality is the overlaying of digitally-created content on top of the real world. AR allows the user to interact with both the real world and digital elements or augmentations. AR can be offered to users via headsets like Microsoft's HoloLens, or through the video camera of a smartphone.

In both practical and experimental implementations, augmented reality can also replace or diminish the user's perception of reality. This altered perception could include simulation of an ocular condition for medical training purposes, or gradual obstruction of reality to introduce a game world. It is worth noting that there is a point when augmented reality and virtual reality likely merge, or overlap. See also, mixed reality.

Particularly in a post-COVID world, AR's applications can meet goals such as facilitating a try-on experience that can lead to direct sales or telling a brand story without the need for an in-person activation or event. We're also seeing AR being used to replace the exhibitor experiences at would-be in-person events, where AR allows the demonstration to come to the user. Now with social distancing mandates restricting in-person presentations, AR is proving even more valuable than ever before as more people begin to see the practical values beyond entertainment.

Virtual reality A high level of VR immersion is achieved by engaging your two most prominent senses, vision and hearing, by using a VR headset and headphones. The VR headset wraps the virtual world or experience nearly to the edge of your natural vision field of view. When you look around, you experience the environment the same as you do when you look around in real life. Headphones amplify the experience by blocking the noise around you, while allowing you to hear the sounds within the VR experience. When you move your head, the sounds within the VR environment move around you like they would in real life. The user becomes immersed within the virtual environment and whilst there, is able to manipulate objects or perform a series of actions.

Virtual Reality has some great applications for training, particularly in healthcare fields or for active shooter preparation. In marketing, companies are implementing VR to enable the consumer to interact with products without having it in their hands — this is particularly applicable for selling luxury properties or furniture that consumers like to touch and feel prior to purchase.

The caveat with virtual reality is consumers cannot typically access this reality without VR goggles, and it is not conducive for a shareable experience that the audience can relive. So, particularly with this tactic, it's crucial to make sure that the "wow-factor" isn't the only goal.

As with anything, knowing what you want to achieve paves the way to get there. Each campaign should start off with establishing the goals. Once companies know what success looks like, they can then utilize creative and effective audience engagement strategies to reach these goals with presentation technology that helps get there.

Every single project is unique and custom. It's impossible to say that one tactic is right for a specific goal. There are ways to think about technology when it comes to those tactics. While a product launch may be great for AR, a real environment visualization is great for VR, or that a multi-user experience is a great way to utilize a permanent interactive display. But the truth is that if you have great strategy and you engage with a great content provider, who truly knows how to develop any type of content, they will be able to guide you in the execution of that tactic and the right technology to support your needs.

------

Dan Pratt is the creative director at Houston-based Vision Production Group.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.